Intellia Therapeutics Demonstrates Pioneering CRISPR/Cas9 Genome Editing Efficiency Data Using Lipid … – GlobeNewswire (press release)
Breaking Finance News |
Intellia Therapeutics Demonstrates Pioneering CRISPR/Cas9 Genome Editing Efficiency Data Using Lipid …
GlobeNewswire (press release) CAMBRIDGE, Mass., March 08, 2017 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapies, today reported updated data showing increased … Intellia Therapeutics Inc (NASDAQ:NTLA) target price raised to $15.00, issued a report today by Zacks Investment … |
